Circulating Tumor DNA and Tissue Testing for Pancreatobiliary Tumors
JAMA Network Open · 12.09.2025 · 8 (9) · e2531373
DOI: 10.1001/jamanetworkopen.2025.31373 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 12.09.2025. Verfasst von Himil Mahadevia und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Missouri-Kansas City. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Pancreatic Neoplasms, Cholangiocarcinoma, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance The prognosis of advanced pancreaticobiliary tumors is poor. Next-generation sequencing (NGS) of tissue samples is utilized to identify actionable alterations, but there are occasional limitations due to inadequate tissue acquisition. Circulating tumor DNA (ctDNA) is an alternative method, but its correlation with tissue-based NGS remains unexplored.
Objectives
To assess the mutation concordance (mCR) rates between ctDNA and tissue testing for patients with pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CC) and to evaluate how ctDNA performs as a treatment response biomarker. Design, Setting, and Participants This retrospective cohort study was conducted among patients with PDAC and CC treated at academic institutions from January 2014 to January 2025. Patients underwent ctDNA testing using 1 platform and tissue NGS testing using 2 platforms. Main Outcomes and Measures mCR, which measures the shared gene alterations observed by both ctDNA and tissue-based NGS testing, was calculated using the Spearman correlation for PDAC and CC. The performance of ctDNA as a treatment response biomarker was assessed by comparing serial ctDNA data with restaging scans and cancer antigen 19-9 levels in patients with PDAC.
Results
Our cohort included 790 patients: 570 with advanced PDAC (265 [46.5%] female; median [IQR] age, 64 [33-84] years) and 220 with advanced CC (95 [43.2%] female; median [IQR] age, 66 [42-88] years). Overall, 461 patients with PDAC (80.9%) and 192 patients with CC (87.2%) underwent ctDNA testing, while 239 patients with PDAC (41.9%) and 70 patients with CC (31.8%) had tissue NGS testing. Among patients with PDAC, 85 of 130 patients (65.4%) showed shared specific gene alterations between ctDNA and tissue testing; there was a significant mCR, with a Spearman correlation of 0.47 (95% CI, 0.28-0.62; P < .001). For patients with CC, 32 of 48 (66.7%) had shared alterations between ctDNA and tissue testing; there was a significant mCR, with a Spearman correlation of 0.56 (95% CI, 0.35-0.70; P < .001). A subgroup analysis of patients with PDAC who underwent serial ctDNA testing suggested that new TP53 subclones and increased ctDNA variant allele frequency levels of TP53 and KRAS were associated with higher odds of progressive disease (eg, increased TP53 frequency: odds ratio, 7.28; 95% CI, 2.15-24.66; P = .001). Conclusions and Relevance In this cohort study of patients with pancreaticobiliary tumors, there was a significant mCR between ctDNA and tissue NGS testing. Additionally, results suggest that ctDNA might detect resistant clones and enable assessment of treatment response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Missouri-Kansas City.
- Division of Hematology-Oncology, Department of Medicine, Mayo Clinic Florida, Jacksonville.
- Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Sciences, Mayo Clinic Florida, Jacksonville.
- Division of Hematology-Oncology, Department of Medicine, Mays Cancer Center, UT Health San Antonio, San Antonio, Texas.
- Division of Hematology-Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix.
- Department of Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
Zitieren
APA
Mahadevia, H., Majeed, U., Patel, J., Ahmed, A. K., Elhariri, A., Albelal, D., Rao, N. N. M., Rachamala, H. K., Mosalem, O., Mukhopadhyay, D., Jones, J., Mahadevan, D., Borad, M. J., Ahn, D., Sonbol, M. B., Tran, N., Mahipal, A., Wee Ma, W., McWilliams, R. R., …, & Babiker, H. (2025). Circulating Tumor DNA and Tissue Testing for Pancreatobiliary Tumors. JAMA Network Open, 8(9), e2531373. https://doi.org/10.1001/jamanetworkopen.2025.31373
Vancouver
Mahadevia H, Majeed U, Patel J, Ahmed AK, Elhariri A, Albelal D, et al. Circulating Tumor DNA and Tissue Testing for Pancreatobiliary Tumors. JAMA Network Open. 2025;8(9):e2531373. doi:10.1001/jamanetworkopen.2025.31373
BibTeX
@article{Mahadevia2025,
author = {Mahadevia, Himil and Majeed, Umair and Patel, Jaydeepbhai and Ahmed, Ahmed K and Elhariri, Ahmed and Albelal, Douaa and Rao, Nakka Naga Malleswara and Rachamala, Hari Krishnareddy and Mosalem, Osama and Mukhopadhyay, Debabrata and Jones, Jeremy and Mahadevan, Daruka and Borad, Mitesh J and Ahn, Daniel and Sonbol, Mohamad Bassam and Tran, Nguyen and Mahipal, Amit and Wee Ma, Wen and McWilliams, Robert R and Halfdanarson, Thor R and Kankeu Fonkoua, Lionel A and Bekaii-Saab, Tanios and Mody, Kabir and Babiker, Hani},
title = {Circulating Tumor DNA and Tissue Testing for Pancreatobiliary Tumors},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {9},
pages = {e2531373},
doi = {10.1001/jamanetworkopen.2025.31373}
}
EUVIMED